13 Nov 2023
// PRESS RELEASE
13 Nov 2023
// PRESS RELEASE
15 Apr 2025
// REUTERS
Latest Content by PharmaCompass
About
CPhI North America CPhI North America
Industry Trade Show
Booth #1145
20-22 May, 2025
Industry Trade Show
Attending
20-22 May, 2025
Industry Trade Show
Attending
23-26 June, 2025
CONTACT DETAILS
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Booth #1145
20-22 May, 2025
Industry Trade Show
Attending
20-22 May, 2025
Industry Trade Show
Attending
23-26 June, 2025
13 Nov 2023
// PRESS RELEASE
13 Nov 2023
// PRESS RELEASE
Details:
The received FDA approval will allow Breckenridge, to launch generic Teriflunomide in the US market from the beginning of 2023 onwards. Teriflunomide, a small molecule is a generic of Aubagio® available in 7mg & 14mg Tablets.
Lead Product(s): Teriflunomide
Therapeutic Area: Neurology Brand Name: Teriflunomide-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Breckenridge Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2021
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Breckenridge Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Teriflunomide – API and Licensing Agreements for Tablets Available
Details : The received FDA approval will allow Breckenridge, to launch generic Teriflunomide in the US market from the beginning of 2023 onwards. Teriflunomide, a small molecule is a generic of Aubagio® available in 7mg & 14mg Tablets.
Product Name : Teriflunomide-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2021
ABOUT THIS PAGE